Evidence map›Paper›PMID 33244057›Full record

ArticleScientific reports2020

Comparative analysis of transcriptomic profile, histology, and IDH mutation for classification of gliomas.

Paul M H Tran, Lynn K H Tran, John Nechtman, Bruno Dos Santos, Sharad Purohit, Khaled Bin Satter, Boying Dun, Ravindra Kolhe, Suash Sharma, Roni Bollag and 1 more

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Multi-Omics Integration for Advancing Glioma Precision Medicine.Annals of clinical and translational neurology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Paul M H TranCenter for Biotechnology and Genomic Medicine, Augusta, USA.
Lynn K H TranCenter for Biotechnology and Genomic Medicine, Augusta, USA.
John NechtmanCenter for Biotechnology and Genomic Medicine, Augusta, USA.
Bruno Dos SantosJinfiniti Precision Medicine, Inc., Augusta, USA.
Sharad PurohitCenter for Biotechnology and Genomic Medicine, Augusta, USA.
Khaled Bin SatterCenter for Biotechnology and Genomic Medicine, Augusta, USA.
Boying DunCenter for Biotechnology and Genomic Medicine, Augusta, USA.
Ravindra KolheDepartment of Pathology, Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA, 30912, USA.
Suash SharmaDepartment of Pathology, Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA, 30912, USA.
Roni BollagDepartment of Pathology, Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA, 30912, USA.
Jin-Xiong SheCenter for Biotechnology and Genomic Medicine, Augusta, USA. jshe@augusta.edu.

Funding

Deep Learning Based Genetic Risk Prediction for Type 1 DiabetesF30DK121461 · NIDDK · AUGUSTA UNIVERSITY · PI TRAN, PAUL · 2019 to 2021
$123k
NIDDK NIH HHS F30 DK121461NIDDK NIH HHS F30DK121461
6 · The paper itself

Abstract

Gliomas are currently classified through integration of histology and mutation information, with new developments in DNA methylation classification. However, discrepancies exist amongst the major classification methods. This study sought to compare transcriptome-based classification to the established methods. RNAseq and microarray data were obtained for 1032 gliomas from the TCGA and 395 gliomas from REMBRANDT. Data were analyzed using unsupervised and supervised learning and other statistical methods. Global transcriptomic profiles defined four transcriptomic glioma subgroups with 91.4% concordance with the WHO-defined mutation subtypes. Using these subgroups, 168 genes were selected for the development of 1000 linear support vector classifiers (LSVC). Based on plurality voting of 1000 LSVC, the final ensemble classifier confidently classified all but 17 TCGA gliomas to one of the four transcriptomic profile (TP) groups. The classifier was validated using a gene expression microarray dataset. TP1 cases include IDHwt, glioblastoma high immune infiltration and cellular proliferation and poor survival prognosis. TP2a is characterized as IDHmut-codel, oligodendrogliomas with high tumor purity. TP2b tissue is mostly composed of neurons and few infiltrating malignant cells. TP3 exhibit increased NOTCH signaling, are astrocytoma and IDHmut-non-codel. TP groups are highly concordant with both WHO integrated histology and mutation classification as well as methylation-based classification of gliomas. Transcriptomic profiling provides a robust and objective method to classify gliomas with high agreement to the current WHO guidelines and may provide additional survival prediction to the current methods.

Indexed as

AstrocytomaBiomarkers, TumorBrain NeoplasmsCell ProliferationDNA MethylationGene ExpressionGene Expression ProfilingGliomaHumansIsocitrate DehydrogenaseMutationNeuronsPrognosisTranscriptomeBiomarkers, TumorIsocitrate Dehydrogenase

Identifiers

PMID33244057
PMCPMC7692499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.